India, Oct. 10 -- The Aveir AR leadless pacemaker made its debut, signalling a new direction in cardiac therapeutics, where a minimally invasive, single-device treatment is now at hand for this complex condition. The first implantation of this new technology to treat Sinus Node Dysfunction (SND) in the country took place successfully by Dr Vanita Arora, Clinical Lead, Cardiac Electrophysiology, Cardiac Pacing and Heart Failure at Apollo Hospitals. SND is a condition in which the natural pacemaker of the heart (the sinoatrial node) is unable to generate electrical impulses at a rate sufficient to satisfy the needs of the body. In older patients, it is relatively more common, but it can be seen in any age group and is usually represented by a combination of slow heartbeats, long pauses and fluctuating irregular rhythms (Atrial Fibrillation). Accurate diagnosis and prompt therapy are critically important issues in improving the overall quality of life in patients, as well as their long-term prognosis. The introduction of the Aveir AR leadless pacemaker represents a paradigm shift from this. This small, intrinsic, self-contained implant is made possible by catheters used to implant the device directly to the chamber of the heart, eliminating the need for leads or surgical pouches under the skin. Use of this technology assures that patients receive the necessary pace support while lowering the risk of infection and complications due to mechanical failure. Furthermore, as the implantation is performed by a minimally invasive procedure, the recovery is shorter, and the patients have a much more comfortable experience. The first successful implantation of the Aveir AR leadless pacemaker by Dr Vanita marks a new era and chapter for cardiac care in India, providing not only a safer or good alternative for the treatment of patients with Sinus Node Dysfunction but also evidencing the growing capability for the country to implant and advance the innovations. htc...